4/8
08:10 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $65.00. They now have a "buy" rating on the stock.
High
Report
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $65.00. They now have a "buy" rating on the stock.
4/1
08:00 am
crvo
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
Low
Report
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
3/28
04:05 pm
crvo
CervoMed to Participate in Upcoming Investor Conferences
Low
Report
CervoMed to Participate in Upcoming Investor Conferences
3/28
08:30 am
crvo
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
Medium
Report
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
3/5
08:00 am
crvo
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
Low
Report
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
2/21
08:00 am
crvo
CervoMed to Participate in the BIO CEO and Investor Conference
Medium
Report
CervoMed to Participate in the BIO CEO and Investor Conference
2/15
08:12 am
crvo
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $50.00 price target on the stock.
2/15
07:17 am
crvo
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $50.00 price target on the stock.
2/12
08:00 am
crvo
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
High
Report
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
2/7
08:30 am
crvo
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
Medium
Report
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
2/5
08:00 am
crvo
CervoMed to Participate in the Emerging Growth Conference 67
Low
Report
CervoMed to Participate in the Emerging Growth Conference 67